CSL, the parent company of CSL Behring, has experienced unprecedented growth over the past few years. We continue to expand our research and development (R&D) of plasma therapeutics and recombinant proteins.
Substitution therapies
Research advances in our recombinant coagulation program have resulted in pre-clinical proof of principle data showing extended half-life for recombinant factor VIIa and factor IX albumin fusion proteins (rVIIa FP and rIX FP).
Last Updated:
3/26/2010 3:46 PM